Treats overactive bladder with symptoms of urge urinary incontinence, urgency, and…. ANDA 211701, held by Unichem. Solifenacin Succinate.
As of Nov 16, 2026, ANDA 211701 (Solifenacin Succinate), held by Unichem, was first approved by FDA on Aug 27, 2019, with 1 approved supplement and 0 published complete response letters.
Solifenacin succinate tablets are indicated for the treatment of adults with overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 27, 2019 | Original application | Approved | None posted |
| Solifenacin Succinate5MG · tablet;oral | Solifenacin Succinate | Rx |
| Solifenacin Succinate10MG · tablet;oral | Solifenacin Succinate | Rx |
| Jan 25, 2021 | Supplement 4Labeling · Standard review | Approved | None posted |
| Aug 27, 2019 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters